TCL Archive Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies November 28, 2014
TCL Archive Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response December 28, 2012
TCL Archive DCPC Board Okays Concept For $10 Mil. Program to Promote Cancer Management In Rural Areas May 25, 1990
